Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

Table 1 Association between clinical markers and Mena^calc expression availability in the TMA cohort (n = 888)

Characteristic		Mena^calc score available		Mena^calc score unavailable		P-value^d
		(n = 403^a)		(n = 483)
		Number	%	Number	%
Menopausal status
	pre	151	37.5	141	29.2	0.0330
	peri	19	4.7	25	5.2
	post	233	57.8	317	65.6
Tumor Size
	<0.5 cm	5	1.2	11	2.3	0.0198
	0.5 to < 1.0 cm	41	10.2	81	16.8
	1.0 to < 2.0 cm	174	43.2	199	41.2
	2 to 5 cm	164	40.7	179	37.0
	>5 cm	19	4.7	13	2.7
Estrogen receptor
	Positive	239	59.3	307	63.6	0.2806
	Negative/Equivocal	104	25.8	103	21.3
	ND^b	60	14.9	73	15.1
Progesterone receptor
	Positive	215	53.3	280	58.0	0.2699
	Negative/Equivocal	128	31.8	130	26.9
	ND^b	60	14.9	73	15.1
Histological grade
	1^c	99	24.6	174	36.0	<0.0001
	2	147	36.4	152	31.5
	3	132	32.8	100	20.7
	ND^b	25	6.2	57	11.8
Adjuvant treatment
	Hormonal	169	41.9	205	42.4	0.0571
	Chemotherapy	78	19.4	64	13.3
	Both	14	3.5	14	2.9
	None	142	35.2	200	41.4
Lymphatic Invasion
	Yes	70	17.4	47	9.7	0.0008
	No	332	82.6	436	90.3
	Missing	1^e		0
Age group
	<50 yrs	157	39.0	149	30.9	0.0115
	≥50 yrs	246	61.0	334	69.1

ISSN: 1471-2407